The Wilms' tumor 1 (WT1) gene, located at chromosome band 11p13, encodes a transcriptional regulator with an N-terminal domain (exons 1-6) and a C-terminal domain containing four zinc-finger motifs (exons [7] [8] [9] [10] . Among the targets of WT1 are many genes involved in apoptosis, cell cycle and proliferation. Originally named for its role in Wilms' tumor, a pediatric kidney malignancy, WT1 has since been found to be implicated in several hematological malignancies, particularly in acute myeloid leukemia (AML). The role of WT1 in AML has been underlined by the finding of WT1 overexpression in 80-90% of AML and WT1 mutations in B10% of AML, but its contribution to leukemogenesis has still not been clarified. 1 Special attention has been paid to the synonymous (Arg301) single-nucleotide polymorphism (SNP) rs16754 of WT1 (903A4G), due to its location in exon 7, a mutational hotspot of WT1 gene in acute leukemia. Recently, WT1 SNP rs16754 was suggested to predict favorable clinical outcome in adults with cytogenetically normal (CN) AML. 2 Conflicting data on the prognostic impact of this SNP have subsequently been reported in pediatric AML. 3, 4 In our study, we assessed the prevalence, the main associated features and the prognostic significance of WT1 SNP rs16754 in a large cohort of adult AML patients.
This study was performed in patients with previously untreated de novo AML (M3-AML excluded) and enrolled on the prospective French ALFA-9801 or ALFA-9802 trials. Details of the treatment protocols have been previously described. 5, 6 These studies were approved by the ethic committees of SaintLouis Hospital (ALFA-9801: number 9959) and Lyon B-Hotel Dieu Hospital (ALFA-9802: number 99017B). Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Overall, 937 patients were included in these trials. This retrospective screening involved 511 patients for whom frozen material collected at time of AML diagnosis was available for molecular analysis. This selected cohort did not significantly differ from the whole cohort in terms of patient characteristics and clinical outcome (data not shown). Genomic DNA was extracted from pre-treatment bone marrow or peripheral blood samples using standard procedures. WT1 exons 7 (including SNP rs16754) and 9 were amplified by PCR, and purified PCR fragments were directly sequenced in both directions, as described elsewhere. 7 Mutations of NPM1, CEBPA, IDH1 and IDH2 exon 4, and FLT3 internal tandem duplication (FLT3-ITD) were investigated as previously reported. 8 Patient characteristics and complete remission rates comparisons were performed using the Fisher exact test for binary variables and the Mann-Whitney test for continuous variables. Overall survival and relapse risk were estimated by the Kaplan-Meier method. For overall survival, patients were censored at last follow-up if alive or at the time of allogeneic transplantation. All survival analyses were performed using a Cox model regression and adjusted on protocol (ALFA-9801 vs ALFA-9802) as covariate. A P-value p0.05 was considered to indicate statistical significance.
The minor allele of WT1 SNP rs16754 was found in 141/511 (27.6%) patients, at the heterozygous state (WT1 AG ) in 123 (24%) and homozygous state (WT1 GG ) in 18 (3.6%). These frequencies are similar to those previously observed in AML patients and in controls. [2] [3] [4] Comparisons of clinical and biological characteristics of patients were performed according to WT1 SNP rs16754 status. In our cohort, patients with at least one minor allele were found to be older than patients with two major alleles (median age: 54 vs 49 years, P ¼ 0.006). As WT1 SNP rs16754 is a germline genetic variation, its frequency is not expected to change with age. Consequently, our finding is very likely to reflect a sampling bias. Patients were not equally distributed across the French-American-British subtypes, with a higher prevalence of M5-AML in patients with at least one minor allele (23% vs 14%, P ¼ 0.02). No other association between WT1 SNP rs16754 status and pre-treatment patient characteristics was found (Table 1 ). In particular, we did not observe any association between the presence of a WT1 mutation and WT1 SNP rs16754 status, in accordance with two previous studies.
2,4 Strikingly, Ho et al. 3 reported that WT1 mutations rarely occur in patients with one minor allele of WT1 SNP rs16754 and are even absent in patients homozygous for the minor allele, suggesting for the first time a link between the acquisition of a WT1 mutation and the SNP rs16754 status.
In univariate analysis, patients with at least one minor allele and patients with two major alleles showed no difference in complete remission rates (82% vs 83%, P ¼ 0.93), 5-year relapse risk (62% vs 67%, P ¼ 0.55) (Figure 1a ) and 5-year overall survival (32% vs 37%, P ¼ 0.11) (Figure 1b) . Likewise, within the subset of CN-AML (n ¼ 208), WT1 SNP rs16754 status had no influence on response to induction chemotherapy (complete remission rates 84% vs 83%, P ¼ 0.99) and no significant impact on a 5-year relapse risk (69% vs 64%, P ¼ 0.08; Figure 1c ) and 5-year overall survival (35% vs 40%, P ¼ 0.38; Figure 1d ). As WT1 SNP rs16754 status was significantly associated with age, we also performed a survival analysis after adjustment on age as continuous covariate, which confirmed the absence of impact of this SNP on patient outcome.
Thus, in our whole cohort of adult AML patients, WT1 SNP rs16754 status did not correlate with clinical outcome, in agreement with Hollink et al. 4 who found no prognostic impact of this SNP in pediatric AML. In contrast, two studies, one performed in adult CN-AML and the other in pediatric AML, reported that the minor allele of WT1 SNP rs16754 predicts significantly improved clinical outcome.
2,3 However, the favorable prognostic impact of WT1 SNP rs16754 status was not found in the same subgroup of patients in both studies. Damm et al. 2 found that the effect of SNP rs16754 was stronger in highrisk patients (that is, CN-AML with a genotype different from NPM1 mutated/FLT3-ITD negative), whereas Ho et al.
3 observed a significant impact of the SNP rs16754 exclusively in patients with low-risk disease (that is, core-binding factor AML and AML with mutated CEBPA or mutated NPM1). We did not observe any prognostic impact of the SNP rs16754 in these subgroups of patients.
The discrepancies between our data and those by Damm et al. 2 and Ho et al. 3 remain elusive. Factors related to patient and disease characteristics (that is, age, study restricted to CN-AML or not, unknown cooperating genetic alterations and so on) may account for the discordant results reported about the prognostic impact of WT1 SNP rs16754 status. Differences in The favorable genotype is defined by the presence of NPM1 mutation or CEBPA mutation(s) without neither FLT3-ITD nor IDH1 mutation.
Letters to the Editor treatment modalities between cooperative groups may also be responsible for these contradictory results. One of the differences between treatment protocols used by the AML SHG and the ALFA is the average cumulative dose of cytarabine, which is slightly higher in AML SHG trials than in ALFA trials. One can hypothesize that leukemic cells carrying the WT1 SNP rs16754 minor allele may be more sensitive to treatment by cytarabine. This could explain why Damm et al. 2 found that the minor allele of WT1 SNP rs16754 confer a favorable prognosis in patients treated within AML SHG 0199 and 0295 trials, whereas we found no significant impact of this SNP in our cohort of adult AML. Of note, differential effects of various dosages of cytarabine in post-remission treatment for AML have been previously shown to be related to somatic molecular abnormalities such as RAS mutations. 9 Synonymous SNPs have often been called silent, but new evidence indicates that they may have a more important role than previously assumed. For example, the C3455 T SNP in multidrug resistance 1 (MDR1) gene changes P-glycoprotein substrate specificity. Several mechanisms, such as alterations of mRNA structure and stability, alterations in a microRNA-binding site, alternate splicing and change in kinetics of translation, have been proposed to explain how synonymous SNPs may alter protein amount, structure and/or activity.
10
WT1 SNP rs16754 is considered as a cis-acting putative regulatory SNP and is associated with allelic imbalance in gene expression, the minor allele being overexpressed compared with the major allele. 11 Of note, WT1 SNP rs16754 status did not correlate with the total WT1 mRNA expression level in two previous studies. 2, 4 Conversely, Ho et al. 3 recently reported that WT1 mRNA expression levels were significantly higher in patients with the minor allele of WT1 SNP rs16754, as well as in patients with a WT1 mutation. Additionally, WT1 SNP rs16754 consists of the replacement of a CGA by a CGG codon, and the latter is used two times more often than the former to encode arginine. Therefore, the presence of the WT1 SNP rs16754 is predicted to increase the rate of translation, which could potentially affect protein folding. Because of its location in WT1 exon 7, SNP rs16754 is not expected to affect splicing. We cannot exclude the possibility that SNP rs16754 is in linkage disequilibrium with another genetic aberration that affects drug metabolism or sensitivity.
Moreover, SNP rs16754 (WT1 GG ) was identified in the tumor tissue of a patient with a hyperplastic intralobar nephrogenic rest, which is recognized as putative precursor lesion of Wilms' tumor. Although the non-neutral effect of SNP rs16754 has not been demonstrated, this observation raises the question whether this WT1 SNP may be also involved in the development of Wilms' tumor. 12 In conclusion, in our large cohort of adult AML patients, WT1 SNP rs16754 status did not show any significant impact on clinical outcome. Because of conflicting data in the literature, further investigations are needed to clarify the relationship between SNP rs16754 and treatment outcome in AML and elucidate the biological effects of this SNP. WT1 SNP rs16754 status, as well as WT1 mutations, should be assessed in future prospective clinical trials to firmly establish their prognostic significance in AML.
Conflict of interest
The authors declare no conflict of interest. 
Acknowledgements

